Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Status:
Recruiting
Trial end date:
2021-09-15
Target enrollment:
Participant gender:
Summary
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological
activity of pemigatinib in subjects with advanced malignancies. This study will have three
parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).